VTVT vs. CTMX, OGI, GNFT, FDMT, IPHA, VTYX, DERM, PBYI, DMAC, and SPRO
Should you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), Journey Medical (DERM), Puma Biotechnology (PBYI), DiaMedica Therapeutics (DMAC), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry.
vTv Therapeutics vs. Its Competitors
vTv Therapeutics (NASDAQ:VTVT) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.
vTv Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.
vTv Therapeutics currently has a consensus price target of $35.50, suggesting a potential upside of 121.74%. CytomX Therapeutics has a consensus price target of $5.33, suggesting a potential upside of 122.22%. Given CytomX Therapeutics' higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than vTv Therapeutics.
CytomX Therapeutics has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, CytomX Therapeutics had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 2 mentions for CytomX Therapeutics and 0 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.00 equaled CytomX Therapeutics'average media sentiment score.
CytomX Therapeutics has a net margin of 28.22% compared to vTv Therapeutics' net margin of 0.00%. vTv Therapeutics' return on equity of -121.46% beat CytomX Therapeutics' return on equity.
17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 1.3% of vTv Therapeutics shares are owned by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
CytomX Therapeutics beats vTv Therapeutics on 12 of the 14 factors compared between the two stocks.
Get vTv Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
vTv Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VTVT) was last updated on 7/9/2025 by MarketBeat.com Staff
